Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers. Laura Bobolts, PharmD, BCOP: There are 3 main cost drivers I typically think about ...
Cost drivers and payer considerations are emphasized for treatment of patients with chronic obstructive pulmonary disease. Jeffrey D. Dunn, PharmD, MBA: Could you summarize the biggest patient cost ...
Commercial SPOS can require ~1,500 kg solvent/kg product, making peak solvent inventory a primary driver of MAQ, control-area allocation, occupancy classification, ventilation, and suite adjacency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results